


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application. The claim amendments are based on the application text as originally filed and do not reflect the Article 19 claim amendments.

Listing of Claims:

Please cancel claims 1-62 without prejudice and add new claims 63-92 as follows:

63. (New) A composition comprising a chemical complex comprising a combination of:
i) a fatty acid ester in the form of a mono-ester or in the form of a di-ester of formula I or isomers thereof,



I

wherein n is 3;

each R¹ and R² is independently selected from the group consisting of H, OH, OM, OR', O-CO-R', straight-chain or branched C₁-C₆ alkyl and straight-chain or branched C₂-C₆ alkenyl, provided that one or two of R¹ and R² is -O-CO-R' and at least one of R₁ and R₂ is OH;

R' is selected from the group consisting of C₆-C₁₄ alkyl and C₆-C₂₀ alkenyl, and M is an alkali metal;
and

- ii) niacinamide, a salt or a derivative thereof, wherein the derivative is selected from the group consisting of niacinamide derivatives with one substitution of the ring with substituents selected from

halogen, NH₂, methyl, OR and SH and from niacinamide derivatives wherein the amide group is in the form of its secondary amide or its tertiary amide.

64. (New) A composition comprising a combination of i) a fatty acid mono-ester or di-ester of formula I and isomers thereof and ii) niacinamide, a salt or a derivative thereof, wherein formula I, n, R¹, R², R', M and the niacinamide derivative are as defined in claim 63.

65. (New) The composition according to claim 63, wherein R' is selected from unsubstituted straight-chain or branched C₁₄-C₂₀ alkenyl.

66. (New) The composition according to claim 65, wherein R' is selected from unsubstituted straight-chain or branched C₆-C₁₂ alkyl.

67. (New) The composition according to claim 63, wherein O-CO-R' is an acyloxy moiety derived from an acid, HO-CO-R', selected from the group consisting of caproic acid, caprylic acid, capric acid, lauric acid and myristic acid.

68. (New) The composition according to claim 67, wherein O-CO-R' is an acyloxy moiety derived from an acid, HO-CO-R', selected from the group consisting of myristoleic acid, palmitic acid, palmitoleic acid, linoleic acid, α -linolenic acid or γ -linolenic acid, ricinoleic acid.

69. (New) The composition according to claim 63, wherein the niacinamide, salt and a derivative thereof is selected from the group consisting of niacinamide, thioniacinamide, 6-amino-niacinamide, N²-methylniacinamide, N²-ethylniacinamide, 6-methoxy-niacinamide and salts thereof.

70. (New) The composition according to claim 63, wherein the pyridine derivative is niacinamide or a salt thereof.

71. (New) The composition according to claim 63, wherein the fatty acid ester and the niacinamide a salt or a derivative thereof are present in a molar ratio of between about 1:10000 to

10000:1, preferably about 1:1000 to 1000:1, more preferably of about 1:100 to 100:1, even more preferably of about 1:10 to 10:1, most preferably of about 1:5 to 5:1 or about 1:2 to 2:1.

72. (New) The composition according to claim 63, wherein the fatty acid ester is racemic, enantiomerically enriched or enantiomerically pure 1-glycerol-monocaprylate and wherein the niacinamide, salt or a derivative thereof is niacinamide.

73. (New) The composition according to claim 63, further comprising one or more excipient(s) or carrier(s) for the formulation of a pharmaceutical, a dietary supplement or a cosmetic.

74. (New) The composition according to claim 73, further comprising one or more therapeutically active agents.

75. (New) The composition according to claim 73, formulated for oral, topical, transdermal, or parenteral administration.

76. (New). The composition according to claim 75, formulated for topical administration.

77. (New) Use of a composition as defined in claim 63, as a dietary supplement.

78. (New) Use of a composition as defined in claim 63, as a cosmetic.

79. (New) A method for treating conditions selected from the group consisting of acne, acne prone skin, irritated skin, dry skin, skin redness, scaly or flaking skin, sunburn comprising administering a composition as defined in claim 63.

80. (New) Use of a composition as defined in claim 63, as an antiseptic agent, disinfectant, bacteriostatic agent, bactericidal agent, protective agent, and/or regenerating agent.

81. (New) A method for the treatment of infections or diseases associated with infections selected from the group consisting of microbial infections, viral infections, infections caused by

parasites, infections caused by fungi in a mammal, including a human, comprising the administration to said mammal an effective amount of a combination of a fatty acid mono-ester or di-ester of formula I and niacinamide, a salt or a derivative thereof,

wherein formula I, n, R¹, R², R', M and the niacinamide derivative are as defined in claim 63.

82. (New) A method for the treatment of viral infections or diseases associated with viral infections in a mammal, including a human, comprising the administration to said mammal an effective amount of a combination of a fatty acid mono-ester or di-ester of formula and niacinamide, a salt or a derivative thereof,

wherein formula I, n, R¹, R², R', M and the niacinamide derivative are as defined in claim 63.

83. (New) The method according to claim 82, for the treatment, alleviation or prevention of infection with virus or a disease associated with infection with virus selected from the group consisting of herpesviruses, adenoviruses, papovaviruses, parvoviruses, picornaviruses, reoviruses, togaviruses, bunyaviruses, orthomyxoviruses, paramyxoviruses, rhabdoviruses, retroviruses, arenaviruses, poxviruses, hepadnaviruses, caliciviruses, flaviviruses, coronaviruses, filoviruses and orthomyxoviruses.

84. (New) The method according to claim 82, for the treatment, alleviation or prevention of infection with virus or a disease associated with infection with virus selected from the group consisting of rhinovirus, influenzavirus, hepatitisvirus, herpesvirus and cytomegalovirus.

85. (New) The method according to claim 82, for the treatment, alleviation or prevention of a disease associated with infection with virus selected from the group consisting of common cold, influenza viral pharyngitis, viral pneumonia and viral hepatitis in an individual.

86. (New) A method for the treatment of a disease and disorder associated with hypersensitivity and/or inflammatory reactions, including a human, comprising the administration to


said mammal an effective amount of a combination of a fatty acid mono-ester or di-ester of formula I and niacinamide, a salt or a derivative thereof,

wherein formula I, n, R¹, R², R', M and the niacinamide derivative are as defined in claim 63.

87. (New) The method according to claim 86, wherein said disease and disorder is selected from the group consisting of hypersensitivity skin disease, pruritus, urticaria, atopic eczema, contact dermatitis, seborrhoeic dermatitis, acne, rosacea, alopecia, vitiligo, psoriasis IgE mediated allergic reactions, asthma, allergic rhinitis, anaphylaxis, autoimmune disease, chronic inflammatory disease, Crohn's disease, ulcerative colitis, rheumatoid arthritis, gout, osteoarthritis, inflammation associated with pain and inflammation associated with cancer.

88. (New) The method according to claim 81, comprising administering a composition comprising a chemical complex comprising a combination of:

i) a fatty acid ester in the form of a mono-ester or in the form of a di-ester of formula I or isomers thereof,



I

wherein n is 3;

each R¹ and R² is independently selected from the group consisting of H, OH, OM, OR', O-CO-R', straight-chain or branched C₁-C₆ alkyl and straight-chain or branched C₂-C₆ alkenyl, provided that one or two of R¹ and R² is -O-CO-R' and at least one of R₁ and R₂ is OH;

R' is selected from the group consisting of C₆-C₁₄ alkyl and C₆-C₂₀ alkenyl, and M is an alkali metal;
and

ii) niacinamide, a salt or a derivative thereof, wherein the derivative is selected from the group consisting of niacinamide derivatives with one substitution of the ring with substituents selected from halogen, NH₂, methyl, OR and SH and from niacinamide derivatives wherein the amide group is in the form of its secondary amide or its tertiary amide.

89. (New) The method according to claim 81, wherein the fatty acid mono-ester or di-ester of formula I and niacinamide, a salt or a derivative thereof are together comprised in a single formulation or are each individually comprised in separate formulations.

90. (New) The method according to claim 81, wherein fatty acid mono-ester or di-ester of formula I and niacinamide, a salt or a derivative thereof is administered by means of oral, topical, transdermal, or parenteral administration, or combinations thereof.

91. (New) The method according to claim 81, wherein the medicament further comprises one or more therapeutically active agents.

92. (New) The method according to claim 91, wherein the separate formulations are administered in a simultaneous or non-simultaneous manner.